Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX
This article was originally published in PharmAsia News
Executive Summary
Cell therapies have shown promise in treating cancer, but turning their possibility into reality so far has eluded the industry. Therefore, news Oct. 16 that one of the latest-stage therapies in development, Takeda/Cell Genesys' GVAX, failed in a second Phase III clinical trial represents, in some ways, a disappointment for the entire space